Oslo, 30 January 2023 - Navamedic ASA (OSE: NAVA), a Nordic pharma company
and reliable provider of high-quality products to hospitals and pharmacies,
today announces it has launched Modifast, a range of low calorie diet (LCD) meal
replacement products, in the Norwegian market. Modifast is part of Navamedic's
growing portfolio of products and solutions aimed at tackling obesity and
consists of supplements, prescription medications, diet replacements and online
patient support portals.
"The experience from Sweden shows that Modifast and obesity related products are
highly suited for online pharmacy sales. The products require significant shelf
space, and we want to provide our consumers with a wide range of flavors and
types of foods. This has supported the decision to launch the product range in
Norway, available to order online," said Kathrine Gamborg, CEO of Navamedic ASA.
Obesity is an increasingly growing public health challenge, and according to the
World Health Organization (WHO), obesity has nearly tripled since 1975. Between
15% and 20% of people in the Nordic population are considered obese, and as a
consequence, the cost of treatment and related complications are increasing.
Weight loss through lifestyle intervention remains a key treatment option in the
management of obesity and is often a prerequisite for patients seeking to
undergo bariatric surgery.
Low calorie diets are full diet replacement products, providing 800-1200
calories per day if all regular food is replaced. Modifast is considered a low
calorie diet (LCD) and is made up of drinks, soups, puddings and pasta dishes,
which have all been developed to contain necessary nutrients. As of January, the
Modifast product range will be available to order online via Farmasiet.no
(Farmasiet), Norway's largest online pharmacy.
"Obesity is a complex disease that, if left untreated, increases the likelihood
of other diseases and conditions such as type 2 diabetes and cardiovascular
disease. At Navamedic, we are excited to be able to introduce Norwegian patients
to a range of LCD products that can safely support their weight loss journey and
improve quality of life," said Jennie Brogårdh, Dietitian at Navamedic ASA.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
About Navamedic ASA
Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please
Modifast is product range consisting of Low Calorie Diet (LCD) meal replacement
products. It is designed to replace all other foods for a limited time period
during weight loss or weight control, without depriving the body of the
nutrients it needs. Modifast cost substitute contains between 800 and 1200 kcal
Modifast has a wide range of products for weight loss, weight control and well
-being. Modifast has been on the market in Europe since 1995 and is recommended
by obesity clinics. How Modifast can help you depends on what your weight goal
is. Different products and approaches work well in different situations. Read
more on www.modifast.no
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.